<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910024</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1778</org_study_id>
    <secondary_id>U1111-1172-6026</secondary_id>
    <secondary_id>CIV-15-09-013868</secondary_id>
    <secondary_id>DRKS00008963</secondary_id>
    <nct_id>NCT02910024</nct_id>
  </id_info>
  <brief_title>Theta-Burst-Stimulation in Early Rehabilitation of Stroke</brief_title>
  <acronym>TheSiReS</acronym>
  <official_title>Theta-Burst-Stimulation in Der frühen Rehabilitation Von Schlaganfallpatienten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present prospective, randomized, controlled, double-blinded trial investigates the&#xD;
      effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after&#xD;
      stroke. Patients with hemipresis will receive either sham or real iTBS over their affected&#xD;
      hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after&#xD;
      the intervention phase and three months after enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, rehabilitation of stroke with hemiparesis mainly includes physiotherapy and&#xD;
      occupational therapy. Yet, the majority of patients retain movement impairment relevant for&#xD;
      activities of daily living. One explanation for this deficit is the insufficient recovery of&#xD;
      connectivity between brain regions after stroke. It is possible to modulate this process by&#xD;
      repetitive transcranial magnetic stimulation (rTMS) using the protocol of intermittent&#xD;
      theta-burst stimulation (iTBS). Previous data indicate that modulation of the motor cortex&#xD;
      with iTBS enhances the effects of subsequent motor training. The present study aims at&#xD;
      investigating whether daily repetitive transcranial magnetic stimulation over 8 days combined&#xD;
      with subsequent physiotherapy leads to better motor recovery, compared with physiotherapy&#xD;
      after sham stimulation. In the first weeks and after three months, motor function, degree of&#xD;
      disability and quality of life are examined in order to evaluate the effects of iTBS in the&#xD;
      rehabilitation of stroke patients.&#xD;
&#xD;
      Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of&#xD;
      Cologne, 20/12/2016): Specification of exclusion criteria.&#xD;
&#xD;
      Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of&#xD;
      Cologne, 15/11/2018): Change of inclusion and exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative grip force</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>grip force as measured with vigorimeter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative grip force</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>grip force as measured with vigorimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>Action Research Arm Test, ARAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>Fugl-Meyer Motor Scale of the upper extremity, FM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke severity</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>National Instituts of Health Stroke Scale, NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of disability</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>modified Rankin Scale, mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motorcortex excitability</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>Motor evoked potential induced by stimulation of the affected motor cortex, MEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motorcortex excitability</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>Resting motor threshold as measured by stimulation of the affected motor cortex, RMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>after 8 days of intervention, and 3 months after enrollment</time_frame>
    <description>EuroQol 5D questionnaire, EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living at admission and discharge in external rehabilitation facility</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Barthel-Index (BI) scores as documented by external rehabilitation facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of rehabilitation after intervention phase</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Days of rehabilitation after intervention phase as documented by external rehabilitation facility</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Real-rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol</intervention_name>
    <description>iTBS applied over ipsilesional M1</description>
    <arm_group_label>Real-rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim Super Rapid2 System, sham-stimulation (in iTBS)</intervention_name>
    <description>iTBS applied with tilted coil over parieto-occipital vertex</description>
    <arm_group_label>Sham-rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  age: 40-90 years&#xD;
&#xD;
          -  ischemic stroke&#xD;
&#xD;
          -  hemiparesis with impaired hand motor function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are legally detained in an official institute (§20 MPG)&#xD;
&#xD;
          -  Participation in clinical trial within the last 12 weeks&#xD;
&#xD;
          -  Electronic implants or ferromagnetic Implants located in the head, neck or thorax&#xD;
             (e.g. clips, intracranial shunt, artificial heart valve, pacemaker)&#xD;
&#xD;
          -  Medication pump (e.g. insulin pump)&#xD;
&#xD;
          -  Metal splinters in eye or head&#xD;
&#xD;
          -  Pregnancy / breastfeeding&#xD;
&#xD;
          -  Severe Neurodegenerative disease&#xD;
&#xD;
          -  Severe Neuroinflammatory disease&#xD;
&#xD;
          -  History of seizures / epilepsy&#xD;
&#xD;
          -  Physical addiction to alcohol, medication, or drugs (excluded: nicotine)&#xD;
&#xD;
          -  Insufficient compliance&#xD;
&#xD;
          -  Present or past malignant tumor involving the central nervous system&#xD;
&#xD;
          -  Severe Psychiatric disease&#xD;
&#xD;
          -  Clinically manifest bilateral hemiparesis or infarcts in the primary motor cortex or&#xD;
             along the tractus corticospinalis in the hemisphere ipsilateral to the hemiparesis&#xD;
&#xD;
          -  Pre-existing cerebral infarctions with hemiparesis or pre-existing cerebral&#xD;
             infarctions in the primary motor cortex or along the tractus corticospinalis,&#xD;
             excluding microangiopathic changes (e.g. clinically asymptomatic lacunae &lt;1cm)&#xD;
&#xD;
          -  Known brain lesion (surgical, traumatic)&#xD;
&#xD;
          -  Evidence for enhanced cerebral pressure&#xD;
&#xD;
          -  Severe cardial dysfunction&#xD;
&#xD;
          -  life expectancy &lt; 12 months&#xD;
&#xD;
          -  NIHSS Score &gt; 20&#xD;
&#xD;
          -  Blood glucose imbalances resistant to treatment (&lt;50 mg/dl or &gt;300 mg/dl)&#xD;
&#xD;
          -  Elevated blood pressure resistant to treatment (RR &gt; 185/110mmHg)&#xD;
&#xD;
          -  Systemic Thrombolysis using r-tPA or thrombectomy within the last 24 hours before&#xD;
             enrollment in study&#xD;
&#xD;
          -  Medication with benzodiazepines, high-potency antipsychotics or tricyclic&#xD;
             antidepressants before hospitalization or long-term during hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gereon R Fink, Univ.-Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gereon R Fink, Univ.-Prof. Dr.</last_name>
    <phone>+49 221 478 4455</phone>
    <email>gereon.fink@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian B Grefkes, Univ.-Prof. Dr.</last_name>
    <phone>+49 221 478 87695</phone>
    <email>christian.grefkes@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln</name>
      <address>
        <city>Cologne</city>
        <state>North Rhine-Westphalia</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Hensel, Dr.</last_name>
      <phone>+49 221 478 82873</phone>
      <email>lukas.hensel@uk-koeln.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Gereon R. Fink</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

